Literature DB >> 1615581

BCG treatment and the importance of an inflammatory response.

D H Schamhart1, K H Kurth, T M de Reijke, R Vleeming.   

Abstract

A prospective study was performed on patients with superficial bladder tumour treated with bacillus Calmette-Guérin (BCG). The kinetics of interleukin-6 (IL-6) titres were monitored in urine collected at regular intervals for 24 h during 14 BCG treatments, each consisting of six weekly intravesical instillations. IL-6 titres were quantified with an ELISA system and compared with a bioassay (biologically active IL-6) system. After instillation, urinary IL-6 titres transiently increased, reaching maximum levels between 2 and 6 h after instillation. IL-6 titres appeared to be significantly correlated with an increase of total cells retrieved by bladder washout 3 h after instillation. The kinetics of the weekly maximum biologically active IL-6 titres indicate that three types of BCG-induced response occur: an "early" response starting at the first instillation; a "late" response after the third instillation; or no IL-6 response. The "early" response appeared to be associated, but not strictly correlated, with an IL-2 response. The results suggest that the effectiveness of BCG treatment is determined by two processes, an inflammatory one, followed by a delayed type of hypersensitivity response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615581     DOI: 10.1007/bf00299717

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  11 in total

1.  Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy.

Authors:  A Böhle; C Nowc; A J Ulmer; J Musehold; J Gerdes; A G Hofstetter; H D Flad
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

Review 2.  The biology of interleukin-6.

Authors:  T Kishimoto
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

Review 3.  Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.

Authors:  M S Soloway; A M Jordan; W M Murphy
Journal:  Prog Clin Biol Res       Date:  1989

4.  Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.

Authors:  A Böhle; J Gerdes; A J Ulmer; A G Hofstetter; H D Flad
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

5.  Interleukin 6 (IL-6) in serum and urine of renal transplant recipients.

Authors:  M H Van Oers; A A Van der Heyden; L A Aarden
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

6.  Production of hybridoma growth factor by human monocytes.

Authors:  L A Aarden; E R De Groot; O L Schaap; P M Lansdorp
Journal:  Eur J Immunol       Date:  1987-10       Impact factor: 5.532

7.  Requirement of a thymus dependent immune response for BCG-mediated antitumor activity.

Authors:  T L Ratliff; D Gillen; W J Catalona
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

8.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

9.  Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer.

Authors:  A Morales
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

10.  Interleukin-6 induced at mucosal surfaces by gram-negative bacterial infection.

Authors:  P de Man; C van Kooten; L Aarden; I Engberg; H Linder; C Svanborg Edén
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

View more
  9 in total

1.  Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.

Authors:  E C de Boer; T M De Reijke; D H Schamhart; P C Vos; K H Kurth
Journal:  Urol Res       Date:  1993

2.  Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).

Authors:  T M de Reijke; P C Vos; E C de Boer; R F Bevers; W H de Muinck Keizer; K H Kurth; D H Schamhart
Journal:  Urol Res       Date:  1993

3.  Interaction between bacteria and the lumenal bladder surface: modulation by pentosan polysulfate, an experimental and theoretical approach with clinical implication.

Authors:  D H Schamhart; E C de Boer; K H Kurth
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

4.  Cytokine-mediated antitumor effect of bacillus Calmette-Guérin on tumor cells in vitro.

Authors:  H Kurisu; H Matsuyama; Y Ohmoto; T Shimabukuro; K Naito
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

5.  On the mode of action of intravesical bacillus Calmette-Guérin: in vitro characterization of BCG-activated killer cells.

Authors:  A Böhle; A Thanhäuser; A J Ulmer; T Mattern; M Ernst; H D Flad; D Jocham
Journal:  Urol Res       Date:  1994

6.  Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer.

Authors:  Mateusz Adamkiewicz; Piotr Bryniarski; Maksymilian Kowalik; Bartłomiej Burzyński; Paweł Rajwa; Andrzej Paradysz
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

7.  Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins.

Authors:  Marcia R Saban; Helen L Hellmich; Cindy Simpson; Carole A Davis; Mark L Lang; Michael A Ihnat; Michael A O'Donnell; Xue-Ru Wu; Ricardo Saban
Journal:  BMC Cancer       Date:  2007-11-02       Impact factor: 4.430

8.  Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG).

Authors:  Marcia R Saban; Cindy Simpson; Carole Davis; Gemma Wallis; Nicholas Knowlton; Mark Barton Frank; Michael Centola; Randle M Gallucci; Ricardo Saban
Journal:  BMC Immunol       Date:  2007-05-16       Impact factor: 3.615

9.  Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha.

Authors:  Marcia R Saban; Michael A O'Donnell; Robert E Hurst; Xue-Ru Wu; Cindy Simpson; Igor Dozmorov; Carole Davis; Ricardo Saban
Journal:  BMC Immunol       Date:  2008-02-11       Impact factor: 3.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.